Ascent Industries Co. (ACNT) 株式分析

企業概要

Ascent Industries Co. is engaged in the development, production, and distribution of specialty chemical solutions, offering a range of products including surfactants, defoamers, lubricating agents, flame retardants, and specialty intermediates in both petroleum-based and bio-based formulations. The company operates within the Basic Materials sector, specifically the Chemicals industry, a segment characterized by the essential provision of raw materials and intermediate goods required for manufacturing processes across various downstream industries. This entity maintains a workforce of 197 employees and holds a market capitalization of $125.57M, with total annual revenue reaching $74.94M. These valuation and revenue figures indicate that Ascent Industries Co. is a mid-cap enterprise operating with a specific niche focus, rather than a large-scale diversified conglomerate, which suggests its market position is defined by specialized product offerings rather than broad market volume.

財務健全性

The company reported a total revenue of $74.94M for the trailing twelve months, yet it recorded a net income loss of $5,584,000 and an EBITDA of $-2,766,000. The significant disparity between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, including potentially high research and development costs for specialty formulations, are currently exceeding gross profit generation. Despite the accounting losses, the company possesses a robust free cash flow of $32.11M, which indicates strong financial flexibility and the ability to fund operations or investments without immediate reliance on external equity financing. The gross margin stands at 23.0%, suggesting that the cost of goods sold consumes 77% of revenue before other expenses are considered. However, the operating margin is negative at -16.8%, while the profit margin is reported at 1.2%, highlighting that while the core product sales retain some value, overhead costs are significantly eroding profitability before the final net income calculation. The balance sheet displays a conservative posture with cash assets of $57.61M against total debt of $13.78M, and a debt-to-equity ratio of 15.84, which implies that equity capital significantly outweighs debt obligations. This liquidity is further reinforced by a current ratio of 6.72, indicating that current assets are more than six times current liabilities and demonstrating ample short-term liquidity to meet obligations. Return on Equity is -6.2% and Return on Assets is -3.4%, metrics that reveal management is currently generating negative returns on the capital base and assets, likely due to the recent net income losses impacting the equity denominator and asset utilization efficiency.

バリュエーション評価

The valuation metrics show a trailing P/E ratio of N/A due to the lack of positive earnings, while the forward P/E is 16.57, implying that the market prices the stock based on expected future earnings recovery rather than current profitability. The price-to-book ratio is 1.43, which indicates that the market is valuing the company at a 43% premium over its net asset value, suggesting confidence in the intangible value of its specialty chemical patents or future growth potential despite current losses. Alternative valuation measures include a price-to-sales ratio of 1.68 and an EV/EBITDA of -29.55, where the negative EV/EBITDA reflects the company's current inability to generate earnings before interest, taxes, depreciation, and amortization, yet the positive P/S ratio suggests the revenue stream is being valued by the market. The stock has a 52-week high of $17.92 and a 52-week low of $11.46, and without the current real-time price provided in the facts, the specific percentage deviation from this range cannot be calculated, though the trading band defines the historical volatility envelope for the share. The beta value is 0.55, indicating that the stock's price volatility is significantly lower than the broader market, suggesting it may serve as a defensive position within a diversified portfolio relative to more volatile large-cap equities.

Growth & Income

Revenue growth year-over-year is 3.5%, whereas earnings growth is N/A due to the absence of positive earnings in the trailing period. The absence of positive earnings growth means that profitability has not expanded faster than revenue, as the company is still navigating a phase of negative net income rather than expanding margins. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that earnings are not distributed to shareholders but are instead retained within the company, potentially to bolster the $57.61M cash position or fund the development of specialty chemical solutions. The overall growth and income profile is characterized by steady revenue expansion coupled with a lack of current dividend income and negative earnings growth, reflecting a reinvestment strategy focused on operational turnaround rather than shareholder yield.